参考文献：M Chen, V Vijay, Q Shi, Z Liu, H Fang, W Tong. 用于研究药物诱导肝损伤的FDA批准药物标签，药物发现今日，16(15-16):697-703, 2011. PMID:21624500 DOI:10.1016/j.drudis.2011.05.007
M Chen, A Suzuki, S Thakkar, K Yu, C Hu, W Tong. DILIrank：按在人类中发展药物诱导肝损伤风险排名的最大参考药物清单。药物发现今日2016, 21(4): 648-653. PMID:26948801 DOI:10.1016/j.drudis.2016.02.015
References:M Chen, V Vijay, Q Shi, Z Liu, H Fang, W Tong. FDA-Approved Drug Labeling for the Study of Drug-Induced Liver Injury, Drug Discovery Today, 16(15-16):697-703, 2011. PMID:21624500 DOI:10.1016/j.drudis.2011.05.007
M Chen, A Suzuki, S Thakkar, K Yu, C Hu, W Tong. DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discov Today 2016, 21(4): 648-653. PMID:26948801 DOI:10.1016/j.drudis.2016.02.015
Easy-cleavage shrink laminate film and the bag using the same
申请人：Idemitsu Petrochemical Co., Ltd.
公开号：EP0903220A2
公开（公告）日：1999-03-24
Disclosed are an easy-cleavage shrink laminate film which is harmless to the environment, easy to tear and moderately shrinkable, and a bag made of the laminate film. The easy-cleavage shrink laminate film 22 has a basic, two-layered structure composed of an easy-cleavage shrink film 19 and a sealant film 21, and may optionally comprise an additional sealant film 21 and/or a substrate film 25 to have a multi-layered structure. The easy-cleavage shrink film 19 comprises from 40 to 85 parts by weight of Ny 6 and from 15 to 60 parts by weight of MXD 6, and this is drawn at an orientation ratio of not smaller than 2.8 times both in the MD direction and in the TD direction and thermally fixed at a heat-treating temperature falling between 120 and 195°C to thereby have a degree of shrinkage of from 15 to 40 % when it is put in hot water at 120°C under pressure of about 2.0 kg/cm2 for 20 minutes.
PHARMACEUTICAL COMPOSITION CONTAINING A CENTRAL OPIOID AGONIST, A CENTRAL OPIOID ANTAGONIST, AND A PERIPHERAL OPIOID ANTAGONIST, AND METHOD FOR MAKING THE SAME
申请人：Harrogate Holdings
公开号：EP1981502A2
公开（公告）日：2008-10-22
Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
申请人：Royds B. Robert
公开号：US20070185145A1
公开（公告）日：2007-08-09
A pharmaceutical composition for treating or preventing a disease, condition or symptoms thereof in a warm-blooded animal including a human, includes a therapeutically effective amount of an opioid agonist exhibiting potential pharmacologically addictive properties in warm blooded animals including humans; a side-effect reducing agent present in amounts sufficient to at least substantially neutralize the adverse side effects of the opioid agonist; an opioid antagonist present in a sequestered form in amounts sufficient to block the pharmacological effect of the opioid agonist upon release from the sequestered form; and a pharmaceutically acceptable carrier.
Heat-accumulating heater
申请人：Komiya Kunihiko
公开号：US20090229593A1
公开（公告）日：2009-09-17
A heat-accumulating heater includes a powdery paraffinic latent heat storage substance sealed in a bag-shaped container. The bag-shaped container includes a plurality of inner container members formed of sheets impermeable to the heat storage substance and water and permeable to air. The inner container members are each received in one of first substantially rectangular outer container members made of rubber that are connected to each other in a row so as to be bendable relative to each other. An air layer is present between each inner container member and the corresponding first outer container member, thereby preventing the inner container member from being pressed against the first outer container member. The first outer container members are in turn received in a second outer container member made of cloth.
METHOD AND COMPOSITION FOR A SACHA INCHI PERENNIAL PLANT EXTRACT BASED HEALTH AND BEAUTY AID
申请人：TRI-K Industries, Inc.
公开号：US20180280287A1
公开（公告）日：2018-10-04
A method and composition for non-invasive treatment of skin aging conditions utilizes a topically applied composition that includes a sustainable non GMO water based extract of peptide Sacha Inchi (hydrolyzed
Plukenetia Volubilis
Seed Extract). The composition utilizes Sacha Inchi to clinically and non-invasively reduce after only 28 days skin sagginess and facial volume contour. Reshaping and resculpting facial skin and reducing dermal non-echogenic surfaces are also accomplished. Increased echogenic surfaces, increased dermal connective tissue and dermal density by restructuring, re-densifying and revitalizing dermis for healthier skin is furthered. The composition was clinically proven to reduce after only 21 days of treatment fine lines, deep wrinkles and facial skin roughness, for a smoother, healthier, younger and less wrinkled skin. The composition was also clinically proven to reduce sebum production, minimize pore size, mattifying skin appearance by sebum regulation and smoothing the appearance of skin after only 21 days of treatment.
